Abstract: Anemia is a very common clinical problem in patients with chronic kidney disease (CKD) and is associated with increased morbidity and mortality in these patients. Erythropoietin is a hormone synthesized in the kidney responsible for red blood cell maturation in the bone marrow. It is defi cient in the majority of patients with advanced kidney disease thereby predisposing to anemia. Since the approval of recombinant human erythropoietin (epoetin alfa) by the US FDA in 1989, epoetin alfa and similar agents now collectively known as erythropoietin stimulating agents (ESA) have become the standard of care for the treatment of the erythropoietin-defi cient anemia that occurs in most patients with CKD. In this review, we have outlined the considerations that need to be taken into account when prescribing ESA for the treatment of anemia in CKD.
Introduction
The National Kidney Foundation of The United States of America (Levey et al 2003) defi nes chronic kidney disease (CKD) as (a) evidence of kidney damage based on abnormal urinalysis results (eg, proteinuria, hematuria) or structural abnormalities observed on ultrasound images or (b) an absolute glomerular fi ltration rate (GFR) of less than 60 mL/min for 3 or more months. Based on this defi nition, guidelines are developed that classify the progression of renal disease into 5 stages, from kidney disease with a preserved GFR to end-stage kidney failure. In Stage 1, there is evidence of kidney damage but GFR is preserved (>90 mL/min). Stage 2 is mild kidney damage with GFR 60-90 mL/min; Stage 3 is moderate kidney damage with GFR 30-59 mL/min; Stage 4 is severe kidney damage with GFR 15-29 mL/min while Stage 5 is end stage renal disease (ESRD) with GFR <15 mL/min. Patients in Stage 5 are often treated with dialysis or kidney transplantation.
CKD is a worldwide public health problem. In the US alone, over 30 million people are affl icted with CKD and the number of patients eventually reaching ESRD is projected to rapidly increase from 450,000 in 2003 to 661,330 by the year 2010 (US RDS 2005) . This high prevalence of CKD, the attendant need for anemia treatment with ESA, and the high costs associated with anemia treatment in CKD calls for a more structured approach on the use of these agents.
Anemia defi ned as hemoglobin concentration below 13.0 g/dL for adult males and post-menopausal women, and a hemoglobin below 12.0 g/dL for pre-menopausal women (World Health Organization 1968) , is a major co-morbidity of CKD and is common in all stages but becomes more pronounced at the latter stages of kidney failure (McClellan et al 2004) . Erythropoietin defi ciency is the most signifi cant cause of anemia in CKD and has been demonstrated to occur at each stage of kidney failure. Because the kidney is the sole source of erythropoietin (EPO) synthesis in adults, reduction in kidney mass as occurs in progressive CKD often results in impairment of EPO production, resulting in anemia. Except for polycystic kidney disease, in which EPO production is preserved due to the fact that the epithelial cells of the cysts produce large amounts of EPO, other causes of kidney failure, including diabetes, hypertension, glomerulonephritis, are universally associated with anemia, which worsens as kidney failure progresses. Although recombinant human erythropoietin is a substitute for the defi ciency observed in CKD, therapy of anemia often involves many other issues detailed below that need to be considered in order to effectively correct anemia, reduce costs and minimize side effects.
Impact of anemia on health
Anemia is a contributing factor in many of the symptoms associated with reduced kidney function. These include fatigue, depression, reduced exercise tolerance and dyspnea. In addition, anemia has direct adverse cardiovascular disease (CVD) consequences (McFarlane et al 2006) , such as left ventricular hypertrophy (LVH) and left ventricular systolic dysfunction, coronary artery disease, and stroke (McLellan et al 2002; Jurkowitz et al 2003) . As a result, patients with anemia due to CKD are at increased risk of hospitalization, increased hospital length of stay, reduced quality of life and mortality (Ma et al 1999; Collins et al 2000) . (Macdougall 2008) . Irrespective of the type of ESA used, the common goal is to correct anemia to target levels. The choice of ESA depends on geographic, economics, industry pressure, and local policies.
Types of erythropoietin stimulating agents (ESA) used in treating anemia in CKD

Considerations in the use of ESA in CKD Etiology of anemia Erythropoietin defi ciency
As shown in Table 2 , EPO defi ciency is by far the leading cause of anemia in patients with CKD. The kidney is the primary site of erythropoietin production in adults (Ratcliffe et al 1995) . Studies utilizing transgenic mice suggest that a population of interstitial fi broblasts (also known as the type I interstitial cell) are the major source of renal erythropoietin synthesis (Maxwell et al 1993) . Defi ciency of EPO, as occurs in patients with CKD, retards maturation of red blood cells from progenitor cells into normoblasts and reticulocytes. Furthermore, defi ciency of EPO decreases the survival of these immature red blood cells, a process known as neocytolysis, thereby resulting in anemia (Righetti et al 2004) . Therefore EPO supplementation is indicated in patients with CKD who manifest anemia. In the absence of other causes, anemia due to EPO defi ciency is often normocytic and normochromic, implying a reduction in number but not quality of these cells. Because of the strong association between CKD and EPO defi ciency, it is often not necessary to measure serum erythropoietin levels prior to treating anemia in these patients. In the presence of other causes of anemia detailed below, therapy with recombinant erythropoietin alone may not necessarily correct anemia, a process known as erythropoietin resistance.
Iron defi ciency
Iron defi ciency is prevalent in CKD and dialysis patients. Iron defi ciency may result from nutritional defi ciency as well as blood losses from occult gastrointestinal hemorrhage, menstruation, and blood draws. Blood draws are particularly signifi cant in hemodialysis patients in whom up to 2 g of iron can be lost per year (KDOQI 2006) . Furthermore, EPO therapy is associated with increased iron utilization, further leading to iron defi ciency. Thus, iron defi ciency will develop in virtually all dialysis patients receiving EPO unless supplemental iron therapy is given intravenously. In fact aggressive diagnosis and therapy of iron defi ciency is the singular cost effective strategy in reducing ESA requirements in CKD patients (Fishbane et al 1995) . Evaluation of iron stores should include red blood cell indices, reticulocyte count, serum iron, total iron binding capacity, percentage transferrin saturation, serum ferritin, and testing for occult blood in stool. Other less commonly used indices of iron defi ciency include reticulocyte Hb Content (CHr) <29 pg and percentage of hypochromic red cells (PHRC) <10%. In patients with CKD, absolute iron defi ciency is defi ned as serum ferritin <100 (<200 for hemodialysis patients) ng/mL and or a transferrin saturation <20%. In contrast, some patients often manifest 'functional' or 'relative iron defi ciency' in which demand for iron in erythropoiesis exceeds supply with the administration of ESA. Iron stores are adequate in functional iron defi ciency; however, there is an inability to adequately mobilize it from the reticuloendothelial system (RES) to support erythropoiesis. Patients with functional iron defi ciency anemia often respond to intravenous iron (Coyne et al 2007) as opposed to a condition termed reticuloendothelial blockade, an extreme case of functional iron defi ciency usually occurring in the setting of acute or chronic infl ammation/infection. This often correlates with a high CRP level and/or a high erythrocyte sedimentation rate. Typically the serum ferritin level is >200 ng/mL but the transferrin saturation <20% in both conditions. Hepcidin, a peptide produced by the liver, inhibits intestinal iron absorption and the release of iron from the RES to circulating transferrin. Serum levels of hepcidin are increased in the setting of infl ammation/infection, and help explain the phenomenon of RES blockade in which stored iron is not released to circulating transferrin, resulting in a high serum ferritin and low transferring saturation level (Wish 2006) . Both functional iron defi ciency and reticuloendothelial blockade may lead to EPO resistance (Tonelli et al 2001; Brugnara 2003) . Serum ferritin and transferrin saturation should be measured before initiating ESA therapy and every 1-3 months during therapy. Patients with stable hemoglobin in the target range who are receiving a stable dose of an ESA should have their hemoglobin checked monthly and any evidence of iron deficiency should be treated with parenteral iron as this route of administration is more effective.
Secondary hyperparathyroidism
Secondary hyperparathyroidism parallels CKD and worsens with its severity. This is due primarily to defi ciency in 1-25 vitD3 and elevated serum inorganic phosphate level both of which stimulate parathyroid hyperplasia and increased parathyroid hormone synthesis, a process called secondary hyperparathyroidism. Secondary hyperparathyroidism increases bone turnover, leading to development of bone cysts and marrow fi brosis, impairing bone marrow function and subsequently anemia (Barany and Muller 2007) . Secondary hyperparathyroidism, if uncontrolled, can lead to erythropoietin resistance. Therefore secondary hyperparathyroidism must be routinely checked and aggressively treated in CKD patients.
Chronic infl ammation
Chronic infl ammation is an important cause of EPO resistance in CKD patients. Chronic infl ammation resulting from rheumatologic diseases (such as arthritis, lupus), chronic infections (such as hepatitis C, soft tissue and bone infections), and failed renal transplants is associated with increased circulating levels of cytokines including CRP, tumor necrosis factor, interferon gama, and interleukins (Tsirpanlis et al 2004) , which impair the erythropoietic response to various stimuli. As CRP has emerged as the most quantifi able marker of infl ammation, it should be routinely investigated when erythropoietin resistance is suspected and no other cause can be identifi ed. In general, levels of CRP >10 mg/L (Ortega et al 2002) , suggest signifi cant infl ammation. Occasionally doubling the erythropoietin dose may overcome the resistance. If no improvement is achieved with doubling the dose, further increments are not likely to yield signifi cant results. In such instances, the erythropoietin doses should not be stopped as this may precipitate neocytolysis, resulting in precipitous decline in red cell count.
Diagnosis of the underlying cause of infl ammation is key in order to eliminate the cause of elevated CRP. If infection is diagnosed specifi c antibiotic therapy or surgical intervention can improve EPO resistance. Similarly, detection and treatment of recurrent vasculitis or malignancy may also have a high impact. If no cause of high CRP is detected a clotted arteriovenous graft should be removed, when appropriate. On rare occasions, if the screen for sepsis is negative and the patient is believed to have a non-infective infl ammatory condition, administration of steroids might be considered (Wanner et al 2007) . Alternatively, such patients should be maintained on regular doses of erythropoietin and periodic red blood cell transfusion.
Pure red cell aplasia
Although rare, administration of ESA may result in formation of anti-erythropoietin antibodies, thereby leading to pure red cell aplasia and erythropoietin resistance (Pollocke et al 2008) . In patients in whom ESA doses have been maximized without effect and no other causes can be identifi ed, serum anti-erythropoietin levels and bone marrow biopsy should be performed. If confi rmed, erythropoietin administration should be ceased and the patient treated with periodic blood transfusions.
Angiotensin converting enzyme inhibitors and receptor blockers
Angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) can contribute to anemia in CKD patients. The observation that ACEI and ARB are preferred drugs in treating post-transplant erythrocytosis support the impact of these agents on anemia. Furthermore, evidence suggests that dialysis patients treated with ACEI and ARB have slightly lower hematocrits than those not on these agents. A circulating natural inhibitor of bone marrow (N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) has been implicated in the pathogenesis of ACEI-induced anemia. The ACE enzyme is responsible for the degradation of AcSDKP, thus blockade of ACE with ACEI leads to increased circulating levels of AcSDKP and therefore bone marrow inhibition ( Le Meur et al 2001) . Secondly, erythroid progenitor cell lines can be stimulated via angiotensin type II receptors therefore blockade of these receptors by ARB may inhibit differentiation of erythroid cell lines (Mohanram et al 2008) . In most instances increase in dose of erythropoietin may overcome the resistance induced by ACEI or ARB. If necessary, modest reduction of doses of ACEI or ARB may be needed in CKD patients with unexplained anemia. Because of the overall cardiovascular benefi t, in the absence of serious complications, complete cessation of ACEI and ARB for the purpose of treating anemia is not indicated.
Hemolytic anemia
Hemolytic anemia is associated with various conditions in CKD patients including systemic lupus erythematosus and microangiopathic hemolytic anemia. Tests of hemolysis such as total bilirubin, lactate dehyrogenase, urine hemosiderin, urine hemoglobin, haptoglobin, and a peripheral smear should be performed to diagnose the presence of hemolysis. By far, haptoglobin is the most specifi c of these tests and a depressed value indicates signifi cant hemolysis. Confi rmation of immune hemolytic anemia by the above tests requires complete hematologic evaluation and possible immunosuppressive therapy that is beyond the scope of this article.
Other causes of anemia
As shown in Table 2 , other rare causes of anemia in CKD patients include folate and B12 defi ciency, hemoglobinopathies, malignancy, and malnutrition. These causes should be routinely investigated and treated.
Target hemoglobin levels
Although the National Kidney Foundation of USA Kidney and Dialysis Outcomes and Quality Initiative (K/DOQI) guidelines on anemia suggested a hemoglobin target range of 11-12 g/dL rather than full normalization, investigators have questioned whether normalizing hemoglobin may lead to additional benefi ts (Foley 2006) . Two large recent randomized controlled trials; Correction of Hemoglobin and Outcomes in Renal Insuffi ciency (CHOIR) (Singh et al 2006) and Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin (CREATE) (Drueke et al 2006) demonstrated increased cardiovascular events and progression to dialysis in patients assigned to the highest hemoglobin targets (>13.0 g/dL), compared with <12 g/dL. This prompted new guidelines published by KDOQI in August 2007 recommending a hemoglobin target range of 11-12 g/dL for patients with CKD (KDOQI 2007) . Subsequently the US Food and Drug Administration (FDA) issued an advisory (Public Health Advisory; Information for Healthcare Professionals) recommending hemoglobin within the range of 10-12 g/dL, with more frequent hemoglobin monitoring (twice weekly), so that early adjustment to ESA therapy may be instituted to avert signifi cant over treatment. Furthermore, ESA therapy with target hemoglobin above 13.0 g/dL has been associated with increased progression of many different types of cancers. The FDA has warned that ESA should be administered only to avoid red blood cell transfusions in cancer patients as they do not improve the outcome of cancer treatment and do not alleviate fatigue or increase energy in these patients.
Whether the increase risk of cardiovascular events, progression to dialysis and cancer progression is due to higher doses of ESA required to achieve those targets, or is due to the increase in hemoglobin per se or a combination of both factors is still a subject of debate. Nonetheless, these potential complications are important considerations when prescribing ESA. In patients with history of cardiovascular disease or cancer, strict adherence to the recommended targets should be the goal.
Route of administration
The route of administration should be taken into account when administering ESA in CKD. Evidence suggests that the subcutaneous route usually results in less frequent injections, reduces ESA requirement and is cost effective than the intravenous route (Tonelli et al 2003) . Despite this fact, many dialysis patients and perhaps nephrology professional staff use the intravenous route since ESA can be conveniently administered during the process of dialysis. For instance, in the USA, most patients on dialysis receive ESA therapy intravenously. In peritoneal dialysis patients and in the non-dialysis CKD population the choice is however limited to subcutaneous administration since patients often are instructed to inject themselves at home without supervision using the least invasive method, which is subcutaneous. In a few patients who do not exhibit adequate response to intravenous ESA administration despite dose adjustment, consideration should be given to switching to the subcutaneous route. When this switch is considered, the subcutaneous dose should be reduced by 30% to avoid the possibility of a sudden rise in hemoglobin above target.
Uncontrolled hypertension
Administration of ESA may be associated with exacerbation of hypertension in about 5% of patients that will require dose adjustment or switching to a different ESA. In the era of new and effective antihypertensive therapy, rarely does full cessation of ESA become necessary. The mechanism of ESA induced hypertension is thought to be related to stimulation of the vascular endothelium by ESA resulting in increased circulating levels of endothelin. Furthermore the increase in hemoglobin associated with ESA therapy may increase blood viscosity resulting in vasospasm. As such routine monitoring of blood pressure is essential in patients treated with ESA (Public Health Advisory; Information for Healthcare Professionals).
Conclusion
Treatment of anemia with ESA in patients with CKD is indicated to improve quality of life and decrease morbidity and mortality. A variety of issues raised in this article need to be taken into account when prescribing ESA to treat anemia in CKD. Furthermore as emerging data suggests that ESA therapy may not be that benign, it is imperative to adhere to strict guidelines and keep hemoglobin levels on the recommended targets ranges. Such action can only be achieved by frequent monitoring of the patient to improve overall outcomes.
